PDL BioPharma Company Profile (NASDAQ:PDLI)

About PDL BioPharma (NASDAQ:PDLI)

PDL BioPharma logoPDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:PDLI
  • CUSIP: 69329Y10
  • Web: www.pdl.com
Capitalization:
  • Market Cap: $396.02 million
  • Outstanding Shares: 160,984,000
Average Prices:
  • 50 Day Moving Avg: $2.42
  • 200 Day Moving Avg: $2.27
  • 52 Week Range: $1.93 - $3.77
P/E:
  • Trailing P/E Ratio: 27.25
  • Foreward P/E Ratio: 10.78
  • P/E Growth: 0.65
Sales & Book Value:
  • Annual Revenue: $103.28 million
  • Price / Sales: 3.87
  • Book Value: $4.65 per share
  • Price / Book: 0.53
Profitability:
  • EBIDTA: $45.51 million
  • Net Margins: 8.02%
  • Return on Equity: 6.06%
  • Return on Assets: 3.87%
Debt:
  • Debt-to-Equity Ratio: 0.15%
  • Current Ratio: 1.98%
  • Quick Ratio: 1.96%
Misc:
  • Average Volume: 1.56 million shs.
  • Beta: 0.6
  • Short Ratio: 9.19
 
Frequently Asked Questions for PDL BioPharma (NASDAQ:PDLI)

What is PDL BioPharma's stock symbol?

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

How will PDL BioPharma's stock buyback program work?

PDL BioPharma announced that its Board of Directors has approved a share buyback program on Saturday, April 8th 2017, which allows the company to buyback $30,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 8.6% of its stock through open market purchases. Stock buyback programs are often a sign that the company's management believes its stock is undervalued.

How were PDL BioPharma's earnings last quarter?

PDL BioPharma, Inc. (NASDAQ:PDLI) released its quarterly earnings results on Wednesday, May, 3rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.05 by $0.03. The firm earned $45.44 million during the quarter. PDL BioPharma had a net margin of 8.02% and a return on equity of 6.06%. View PDL BioPharma's Earnings History.

When will PDL BioPharma make its next earnings announcement?

PDL BioPharma is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for PDL BioPharma.

Where is PDL BioPharma's stock going? Where will PDL BioPharma's stock price be in 2017?

2 brokers have issued 12-month price objectives for PDL BioPharma's stock. Their predictions range from $3.50 to $4.00. On average, they expect PDL BioPharma's share price to reach $3.75 in the next twelve months. View Analyst Ratings for PDL BioPharma.

What are analysts saying about PDL BioPharma stock?

Here are some recent quotes from research analysts about PDL BioPharma stock:

  • 1. According to Zacks Investment Research, "PDL BioPharma reported better than expected earnings in the first quarter of 2017 whereas revenue significantly decreased year over year. The company is focused on acquiring and managing income-generating assets. PDL BioPharma has royalty agreements with several companies, whereby it has royalty rights on product sales. We are positive on the company’s recent strategic shift, whereby it is making equity investments in product-focused companies. However, the company’s dependence on revenues from royalties is not a risk-free strategy. Moreover, the company’s top line declined materially after it stopped receiving payments from certain Queen et al. patent license. The decrease in royalties from PDL's Queen et al. patents is due to the expiration of the patent license agreement with Genentech. PDL BioPharma’s shares have underperformed the Medical-Biomedical/Genetics industry in the past one year." (5/15/2017)
  • 2. Cowen and Company analysts commented, "PDL reported an in-line Q1 with both total revenue ($45MM vs $43MM) and EPS." (5/3/2017)

Are investors shorting PDL BioPharma?

PDL BioPharma saw a increase in short interest during the month of June. As of June 30th, there was short interest totalling 16,311,376 shares, an increase of 13.0% from the June 15th total of 14,430,001 shares. Based on an average daily trading volume, of 1,799,346 shares, the days-to-cover ratio is presently 9.1 days. Currently, 10.4% of the shares of the stock are sold short.

Who are some of PDL BioPharma's key competitors?

Who are PDL BioPharma's key executives?

PDL BioPharma's management team includes the folowing people:

  • John Peter McLaughlin, President, Chief Executive Officer, Director
  • Peter S. Garcia, Chief Financial Officer, Vice President
  • Steffen Pietzke CPA, Chief Accounting Officer, Vice President - Finance
  • Christopher Lewis Stone J.D., Vice President, General Counsel, Secretary
  • Danny Hart, Vice President - Business Development
  • Harold E. Selick Ph.D., Lead Independent Director
  • Paul R. Edick, Independent Director
  • David W. Gryska, Independent Director
  • Jody S. Lindell, Independent Director
  • Samuel R. Saks M.D., Independent Director

Who owns PDL BioPharma stock?

PDL BioPharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (3.00%), Bank of Montreal Can (0.24%), Strs Ohio (0.17%), Eqis Capital Management Inc. (0.14%), Aperio Group LLC (0.13%) and Shell Asset Management Co. (0.10%). Company insiders that own PDL BioPharma stock include Peter S Garcia and Steffen Pietzke. View Institutional Ownership Trends for PDL BioPharma.

Who sold PDL BioPharma stock? Who is selling PDL BioPharma stock?

PDL BioPharma's stock was sold by a variety of institutional investors in the last quarter, including Aperio Group LLC, Strs Ohio, Bank of Montreal Can and Acadian Asset Management LLC. View Insider Buying and Selling for PDL BioPharma.

Who bought PDL BioPharma stock? Who is buying PDL BioPharma stock?

PDL BioPharma's stock was bought by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. Company insiders that have bought PDL BioPharma stock in the last two years include Peter S Garcia and Steffen Pietzke. View Insider Buying and Selling for PDL BioPharma.

How do I buy PDL BioPharma stock?

Shares of PDL BioPharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PDL BioPharma's stock price today?

One share of PDL BioPharma stock can currently be purchased for approximately $2.48.


MarketBeat Community Rating for PDL BioPharma (NASDAQ PDLI)
Community Ranking:  1.1 out of 5 ()
Outperform Votes:  28 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  133
MarketBeat's community ratings are surveys of what our community members think about PDL BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for PDL BioPharma (NASDAQ:PDLI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $3.75 (51.21% upside)

Analysts' Ratings History for PDL BioPharma (NASDAQ:PDLI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/3/2017Cowen and CompanyReiterated RatingHoldHighView Rating Details
12/22/2016Piper Jaffray CompaniesInitiated CoverageOverweight$4.00N/AView Rating Details
2/23/2016Royal Bank Of CanadaLower Price TargetSector Perform$5.00 -> $4.00N/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for PDL BioPharma (NASDAQ:PDLI)
Earnings by Quarter for PDL BioPharma (NASDAQ:PDLI)
Earnings History by Quarter for PDL BioPharma (NASDAQ PDLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017        
5/3/2017Q1 2017$0.05$0.08$45.44 millionViewListenView Earnings Details
11/3/2016Q316$0.08$0.08$50.69 million$53.60 millionViewN/AView Earnings Details
8/4/2016Q216$0.08$0.09$33.46 million$21.00 millionViewN/AView Earnings Details
5/4/2016Q116$0.50$0.52$142.05 million$103.10 millionViewN/AView Earnings Details
2/22/2016Q415$0.54$0.61$149.20 million$178.10 millionViewListenView Earnings Details
11/4/2015Q315$0.61$0.42$164.80 million$124.60 millionViewN/AView Earnings Details
8/5/2015Q215$0.52$0.47$137.75 million$138.10 millionViewN/AView Earnings Details
5/6/2015Q115$0.52$0.50$140.80 million$149.71 millionViewN/AView Earnings Details
2/23/2015Q414$0.57$0.32$158.15 million$117.10 millionViewListenView Earnings Details
11/10/2014Q314$0.56$0.61$165.10 million$164.60 millionViewN/AView Earnings Details
8/18/2014Q214$0.46$0.52$134.07 million$162.80 millionViewListenView Earnings Details
5/12/2014Q114$0.45$0.44$130.93 million$139.70 millionViewN/AView Earnings Details
3/3/2014Q413$0.43$0.39$115.22 million$110.10 millionViewN/AView Earnings Details
11/6/2013Q313$0.37$0.36$97.09 million$97.30 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.54$0.62$138.20 million$143.60 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.35$0.36$91.69 million$91.80 millionViewN/AView Earnings Details
3/1/2013Q4 2012$0.31$0.34$86.08 million$86.10 millionViewN/AView Earnings Details
11/5/2012Q312$0.33$0.32$85.03 million$85.20 millionViewN/AView Earnings Details
8/2/2012$0.44$0.52ViewN/AView Earnings Details
5/3/2012$0.27$0.29ViewN/AView Earnings Details
2/23/2012$0.28$0.24ViewN/AView Earnings Details
11/9/2011$0.27$0.28ViewN/AView Earnings Details
7/27/2011$0.39$0.39ViewN/AView Earnings Details
4/27/2011$0.24$0.25ViewN/AView Earnings Details
2/28/2011$0.21$0.20ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for PDL BioPharma (NASDAQ:PDLI)
Current Year EPS Consensus Estimate: $0.19 EPS
Next Year EPS Consensus Estimate: $0.23 EPS

Dividends

Dividend History by Quarter for PDL BioPharma (NASDAQ PDLI)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/4/2016quarterly$0.056.25%6/2/20166/6/20166/13/2016
2/1/2016quarterly$0.057.27%3/2/20163/4/20163/11/2016
2/2/2015quarterly$0.158.22%6/1/20166/5/20166/12/2016
1/30/2015quarterly$0.158.23%6/3/20156/5/20156/12/2015
1/30/2015quarterly$0.158.23%3/3/20153/5/20153/12/2015
1/30/2015quarterly$0.158.23%12/2/201512/4/201512/11/2015
1/30/2015quarterly$0.158.23%9/2/20159/4/20159/11/2015
1/31/2014quarterly$0.156.59%9/3/20149/5/20149/12/2014
1/31/2014quarterly$0.156.59%3/3/20143/5/20143/12/2014
1/31/2014quarterly$0.156.59%12/3/201412/5/201412/12/2014
1/31/2014quarterly$0.156.59%6/3/20146/5/20146/12/2014
1/31/2013quarterly$0.158.72%12/3/201312/5/201312/12/2013
1/31/2013quarterly$0.158.72%6/3/20136/5/20136/12/2013
1/31/2013quarterly$0.158.72%9/3/20139/5/20139/12/2013
1/30/2013quarterly$0.158.72%3/1/20133/5/20133/12/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for PDL BioPharma (NASDAQ:PDLI)
Insider Ownership Percentage: 2.20%
Institutional Ownership Percentage: 84.44%
Insider Trades by Quarter for PDL BioPharma (NASDAQ:PDLI)
Institutional Ownership by Quarter for PDL BioPharma (NASDAQ:PDLI)
Insider Trades by Quarter for PDL BioPharma (NASDAQ:PDLI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/24/2017Peter S GarciaVPBuy25,000$1.98$49,500.00View SEC Filing  
8/9/2016Peter S GarciaVPBuy10,000$3.00$30,000.00View SEC Filing  
12/15/2015Peter S. GarciaCFOBuy5,000$3.64$18,200.00View SEC Filing  
12/14/2015Peter S. GarciaCFOBuy10,000$3.42$34,200.00View SEC Filing  
12/7/2015Steffen PietzkeCAOBuy20,590$3.64$74,947.60View SEC Filing  
8/14/2015Peter S GarciaCFOBuy20,000$5.83$116,600.00View SEC Filing  
11/26/2014Harold E SelickDirectorBuy6,000$8.08$48,480.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for PDL BioPharma (NASDAQ:PDLI)
Latest Headlines for PDL BioPharma (NASDAQ:PDLI)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to PDL BioPharma, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 7:47 PM
finance.yahoo.com logoPDL BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : PDLI-US : July 21, 2017
finance.yahoo.com - July 22 at 7:29 AM
americanbankingnews.com logoPDL BioPharma, Inc. (NASDAQ:PDLI) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - July 19 at 8:00 PM
americanbankingnews.com logoPDL BioPharma, Inc. (PDLI) Short Interest Up 13.0% in June
www.americanbankingnews.com - July 15 at 7:16 AM
finance.yahoo.com logoETFs with exposure to PDL BioPharma, Inc. : July 13, 2017
finance.yahoo.com - July 14 at 7:19 AM
americanbankingnews.com logoPDL BioPharma, Inc. (NASDAQ:PDLI) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 11 at 12:40 PM
finance.yahoo.com logoPDL BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : PDLI-US : July 10, 2017
finance.yahoo.com - July 11 at 6:31 AM
americanbankingnews.com logo$0.09 Earnings Per Share Expected for PDL BioPharma, Inc. (PDLI) This Quarter
www.americanbankingnews.com - July 6 at 4:24 PM
finance.yahoo.com logoETFs with exposure to PDL BioPharma, Inc. : July 3, 2017
finance.yahoo.com - July 4 at 5:51 AM
americanbankingnews.com logoShort Interest in PDL BioPharma, Inc. (PDLI) Grows By 16.1%
www.americanbankingnews.com - June 28 at 7:12 AM
finance.yahoo.com logoETFs with exposure to PDL BioPharma, Inc. : June 20, 2017
finance.yahoo.com - June 21 at 1:32 AM
finance.yahoo.com logoPDL BioPharma, Inc. :PDLI-US: Earnings Analysis: Q1, 2017 By the Numbers : June 19, 2017
finance.yahoo.com - June 19 at 7:53 PM
finance.yahoo.com logoPDL BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : PDLI-US : June 19, 2017
finance.yahoo.com - June 19 at 10:31 AM
americanbankingnews.com logoZacks: Analysts Anticipate PDL BioPharma, Inc. (PDLI) to Announce $0.09 Earnings Per Share
www.americanbankingnews.com - June 12 at 4:48 PM
seekingalpha.com logoPDL BioPharma (PDLI) Presents At Jefferies 2017 Global Healthcare Conference
seekingalpha.com - June 7 at 7:02 PM
prnewswire.com logoNoden Pharma Notified of ANDA Filing for Tekturna® - PR Newswire - PR Newswire (press release)
www.prnewswire.com - June 6 at 8:21 AM
finance.yahoo.com logoNoden Pharma Notified of ANDA Filing for Tekturna®
finance.yahoo.com - June 5 at 8:23 AM
americanbankingnews.com logoValuEngine Downgrades PDL BioPharma Inc (PDLI) to Hold
www.americanbankingnews.com - June 3 at 5:40 PM
finance.yahoo.com logoPDL BioPharma to Present at the Jefferies 2017 Healthcare Conference
finance.yahoo.com - June 1 at 7:57 PM
seekingalpha.com logoPDL BioPharma: Now Is The Time To Buy - Seeking Alpha
seekingalpha.com - May 19 at 11:57 AM
americanbankingnews.com logo Brokerages Expect PDL BioPharma Inc (PDLI) to Announce $0.04 EPS
www.americanbankingnews.com - May 16 at 10:46 AM
americanbankingnews.com logoPDL BioPharma Inc (PDLI) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - May 15 at 12:22 PM
finance.yahoo.com logoLENSAR® And PDL BioPharma Complete Strategic Financial Restructuring Of LENSAR
finance.yahoo.com - May 11 at 8:32 AM
americanbankingnews.com logoPDL BioPharma Inc (PDLI) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - May 6 at 1:00 AM
streetinsider.com logoLENSAR Receives FDA Clearances for Laser Cataract Platform Integration With OCULUS Pentacam Tomographers (PDLI)
www.streetinsider.com - May 5 at 7:26 PM
finance.yahoo.com logoLENSAR® Receives FDA Clearances for Laser Cataract Platform Integration With OCULUS Pentacam® Tomographers
finance.yahoo.com - May 5 at 7:26 PM
americanbankingnews.com logoPDL BioPharma Inc (PDLI) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 5 at 2:30 PM
finance.yahoo.com logoEdited Transcript of PDLI earnings conference call or presentation 3-May-17 8:30pm GMT
finance.yahoo.com - May 4 at 8:06 AM
americanbankingnews.com logoPDL BioPharma's (PDLI) "Hold" Rating Reiterated at Cowen and Company
www.americanbankingnews.com - May 4 at 12:06 AM
americanbankingnews.com logoCowen and Company Reiterates "Hold" Rating for PDL BioPharma Inc (PDLI)
www.americanbankingnews.com - May 4 at 12:00 AM
rttnews.com logoEARNINGS SUMMARY: Details of PDL BioPharma Inc. Q1 Earnings Report
www.rttnews.com - May 3 at 7:53 PM
finance.yahoo.com logoInvestor Network: PDL BioPharma, Inc. to Host Earnings Call
finance.yahoo.com - May 3 at 7:53 PM
finance.yahoo.com logoPDL BioPharma Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 7:53 PM
finance.yahoo.com logoPDL BioPharma posts 1Q profit
finance.yahoo.com - May 3 at 7:53 PM
americanbankingnews.com logoPDL BioPharma (PDLI) Receives Media Impact Rating of 0.69
www.americanbankingnews.com - May 2 at 2:50 PM
americanbankingnews.com logoPDL BioPharma (PDLI) Earning Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 28 at 1:01 AM
finance.yahoo.com logoPDL BioPharma to Announce First Quarter 2017 Financial Results on May 3, 2017
finance.yahoo.com - April 26 at 6:05 PM
finance.yahoo.com logoPDL BioPharma, Inc. – Value Analysis (NASDAQ:PDLI) : April 26, 2017
finance.yahoo.com - April 26 at 6:05 PM
finance.yahoo.com logoPDL BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : PDLI-US : April 25, 2017
finance.yahoo.com - April 25 at 10:21 AM
finance.yahoo.com logoETFs with exposure to PDL BioPharma, Inc. : April 24, 2017
finance.yahoo.com - April 24 at 5:52 PM
americanbankingnews.com logoPDL BioPharma (PDLI) Receives Coverage Optimism Rating of 0.44
www.americanbankingnews.com - April 24 at 3:22 PM
finance.yahoo.com logoPDL BioPharma Announces Settlement of Keytruda Patent Infringement Lawsuit with Merck
finance.yahoo.com - April 24 at 12:29 PM
finance.yahoo.com logoPDL BioPharma to be paid $19.5 million by Merck to settle Keytruda patent suit
finance.yahoo.com - April 24 at 12:29 PM
americanbankingnews.com logoPDL BioPharma (PDLI) Earning Somewhat Critical News Coverage, Study Shows
www.americanbankingnews.com - April 21 at 9:21 PM
americanbankingnews.com logoPDL BioPharma (PDLI) Board of Directors Announces Stock Repurchase Plan
www.americanbankingnews.com - April 8 at 8:34 AM
finance.yahoo.com logoPDL BioPharma to Hold Annual Meeting of Stockholders on June 9, 2017
finance.yahoo.com - April 7 at 11:49 AM
americanbankingnews.com logoTheStreet Downgrades PDL BioPharma Inc (PDLI) to D+
www.americanbankingnews.com - April 5 at 3:16 PM
finance.yahoo.com logoPDL BioPharma (PDLI) Up 5.9% Since Earnings Report: Can It Continue?
finance.yahoo.com - April 3 at 9:24 AM
americanbankingnews.com logoInsider Buying: PDL BioPharma Inc (PDLI) VP Acquires 25,000 Shares of Stock
www.americanbankingnews.com - March 27 at 11:04 PM
seekingalpha.com logoPDL BioPharma (PDLI) Presents At Oppenheimer 27th Annual Healthcare Conference
seekingalpha.com - March 21 at 6:58 PM

Social

Chart

PDL BioPharma (PDLI) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff